Regulating consumer use of transcranial direct current stimulation devices

Farrell, Anne-Maree; Carter, Adrian; Rogasch, Nigel C.; Fitzgerald, Paul B.

doi:10.5694/mja17.00778

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that evidence on the safety and efficacy of these cognitive enhancement tools is in its infancy, appropriate regulation and safeguards are needed to prevent potential harm. For example, misuse of commercially available transcranial direct current stimulation devices (Farrell et al, 2018) is an issue for users who are unaware of or ignore risks associated with overuse. The current regulatory framework in Australia for non-therapeutic uses of new neurotechnologies is inadequate (Farrell et al, 2018).…”

Section: Responsible Innovation Through Community Engagementmentioning

confidence: 99%

“…For example, misuse of commercially available transcranial direct current stimulation devices (Farrell et al, 2018) is an issue for users who are unaware of or ignore risks associated with overuse. The current regulatory framework in Australia for non-therapeutic uses of new neurotechnologies is inadequate (Farrell et al, 2018). The ABA proposes to facilitate collaborations between scientists, clinicians, developers, and legal scholars to address this regulatory void.…”

Section: Responsible Innovation Through Community Engagementmentioning

confidence: 99%

See 1 more Smart Citation

A Neuroethics Framework for the Australian Brain Initiative

Carter¹,

Richards²,

Apthorp³

et al. 2019

Neuron

Self Cite

View full text Add to dashboard Cite

Neuroethics is central to the Australian Brain Initiative's aim to sustain a thriving and responsible neurotechnology industry. Diverse and inclusive community and stakeholder engagement and a trans-disciplinary approach to neuroethics will be key to the success of the Australian Brain Initiative. Australia has a strong history of neuroscience discovery and neurotechnology translation, which led to the launch of medical device companies including in hearing (Cochlear), vision (Bionic Eye), pain (Saluda Medical), epilepsy management (IBM Research Australia), cognitive assessment (Cogstate), and brain-computer interfaces (EMOTIV). The Australian Brain Alliance (ABA) aims to further catalyze technological and scientific advances to sustain a thriving neurotechnology environment in Australia and engage global collaboration across industry and science. Major investment in an Australian Brain Initiative is needed to coordinate and build capacity in basic neuroscience and provide discovery pipelines that will translate discovery into tangible therapeutic applications. The ABA brings together diverse strengths in Australian brain science across cellular and molecular neuroscience; neurophysiology; clinical, cognitive, and behavioral neuroscience; psychology; computational neuroscience; and neuroengineering to work with industry partners and end-users. The goals are to develop more accurate methods of brain recording and stimulation, wearable devices that capitalize on recent advances in artificial intelligence (AI) and machine learning, and new methods for cognitive assessment and behavioral adaptation to better prevent, predict, and treat mental and neurological disorders and maximize learning across the lifespan.

show abstract

Section: Responsible Innovation Through Community Engagementmentioning

confidence: 99%

Section: Responsible Innovation Through Community Engagementmentioning

confidence: 99%